These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25046810)

  • 41. Factors associated with long-term pessary use in women with symptomatic pelvic organ prolapse.
    Mao M; Xu T; Kang J; Zhang Y; Ai F; Zhou Y; Zhu L
    Climacteric; 2019 Oct; 22(5):478-482. PubMed ID: 30897024
    [No Abstract]   [Full Text] [Related]  

  • 42. An Arterial Vaginal Bleed Resulting from Short-Term Pessary Use: A Case Report.
    Rieben K; Epp A
    J Obstet Gynaecol Can; 2021 Apr; 43(4):503-505. PubMed ID: 33153940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Complications related to pessary use in the treatment of female pelvic organ prolapse].
    Mooij R; Potijk TM; Schrickx JA
    Ned Tijdschr Geneeskd; 2021 Jul; 165():. PubMed ID: 34346635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse events associated with pessary use over one year among women attending a pessary care clinic.
    Kakkar A; Reuveni-Salzman A; Bentaleb J; Belzile E; Merovitz L; Larouche M
    Int Urogynecol J; 2023 Aug; 34(8):1765-1770. PubMed ID: 36715742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Entrapped vaginal pessary presented with frequency and urge incontinence.
    Chou YC; Yu KJ
    J Chin Med Assoc; 2003 Mar; 66(3):181-3. PubMed ID: 12779040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ESTROgen use for complications in women treating pelvic organ prolapse with vaginal PESSaries (ESTRO-PESS)-a randomized clinical trial.
    de Albuquerque Coelho SC; Giraldo PC; Brito LGO; Juliato CRT
    Int Urogynecol J; 2021 Jun; 32(6):1571-1578. PubMed ID: 33501563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rare case of neglected pessary presenting with concealed vaginal hemorrhage.
    Andrikopoulou M; Lazarou G
    Female Pelvic Med Reconstr Surg; 2015; 21(1):e1-2. PubMed ID: 25185620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of pelvic organ prolapse ring pessary therapy on intravaginal microbial flora.
    Yoshimura K; Morotomi N; Fukuda K; Hachisuga T; Taniguchi H
    Int Urogynecol J; 2016 Feb; 27(2):219-27. PubMed ID: 26377332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A simplified protocol for pessary management.
    Wu V; Farrell SA; Baskett TF; Flowerdew G
    Obstet Gynecol; 1997 Dec; 90(6):990-4. PubMed ID: 9397117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of estrogen on vaginal complications of pessary use: a systematic review and meta-analysis.
    Ai F; Wang Y; Wang J; Zhou L; Wang S
    Climacteric; 2022 Dec; 25(6):533-542. PubMed ID: 35695119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Changes in the vaginal flora caused by supporting pessary treatment in pregnancy].
    Jorde A; Kästli K; Hamann B; Pockrandt H
    Zentralbl Gynakol; 1983; 105(13):855-62. PubMed ID: 6613402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The history and usage of the vaginal pessary: a review.
    Oliver R; Thakar R; Sultan AH
    Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):125-30. PubMed ID: 21255901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful use of ring pessary with support for advanced pelvic organ prolapse.
    Ding J; Chen C; Song XC; Zhang L; Deng M; Zhu L
    Int Urogynecol J; 2015 Oct; 26(10):1517-23. PubMed ID: 25982787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaginal microflora following the use of a disposable home-use vaginal device and a commercially available ring pessary for pelvic organ prolapse management: a randomized controlled trial.
    Ziv E; Keller N; Erlich T
    Arch Gynecol Obstet; 2024 Feb; 309(2):571-579. PubMed ID: 37882871
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sexual activity predicts continued pessary use.
    Brincat C; Kenton K; Pat Fitzgerald M; Brubaker L
    Am J Obstet Gynecol; 2004 Jul; 191(1):198-200. PubMed ID: 15295365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytologic changes associated with vaginal pessary use. With special reference to the presence of Actinomyces.
    Christ ML; Haja J
    Acta Cytol; 1978; 22(3):146-9. PubMed ID: 277039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How often should ring pessaries be removed or changed in women with advanced POP? A prospective observational study.
    Miceli A; Fernández-Sánchez M; Dueñas-Díez JL
    Int Urogynecol J; 2021 Jun; 32(6):1471-1478. PubMed ID: 33620536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The characteristics and satisfaction of the patients using vaginal pessaries.
    Sitavarin S; Wattanayingcharoenchai R; Manonai J; Sarit-apirak S; Chittacharoen A
    J Med Assoc Thai; 2009 Jun; 92(6):744-7. PubMed ID: 19530578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of women with continued use of vaginal pessaries.
    Lewthwaite BJ; Staley D; Girouard L; Maslow K
    Urol Nurs; 2013; 33(4):171-6. PubMed ID: 24079114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pessary test to predict postoperative urinary incontinence in women undergoing hysterectomy for prolapse.
    Liang CC; Chang YL; Chang SD; Lo TS; Soong YK
    Obstet Gynecol; 2004 Oct; 104(4):795-800. PubMed ID: 15458904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.